Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
|Articles|May 1, 2007

Applied Clinical Trials

  • Applied Clinical Trials-05-01-2007
  • Volume 0
  • Issue 0

eShowcase: CTSD Version 2.5

CTSD Version 2.5 provides improved data visualization and enhanced user interface

CTSD Version 2.5 provides improved data visualization and enhanced user interface

Phase Forward (Waltham, MA) has released Version 2.5 of its Clinical Trials Signal Detection (CTSD) system. CTSD detects, evaluates, and tracks potential safety signals, which allows biopharmaceutical companies to analyze and classify potential safety signals, develop a product safety profile, and make more informed decisions earlier in the drug development process.

CTSD 2.5 adds an enhanced user interface that features summary displays, data visualization tools, and access to trial data without programming. The user interface's interactive displays facilitate safety review workflow by including patient level drill downs, Lab Trend graphs, an Exposure Summary graph, and Kaplan-Meier plots. It also offers Hy's Law alerts and a full set of Standardized MedDRA Queries (SMQs).

The product is integrated with Phase Forward's Web Submission Data Manager (WebSDM) platform and offers CDISC support.

Phase Forward, (781) 890-7878, www.phaseforward.com

Articles in this issue


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.